Free Trial

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

$84.85
+2.71 (+3.30%)
(As of 07/19/2024 ET)

Axsome Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 13 Wall Street analysts who have issued ratings for Axsome Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 1 has given a hold rating, and 12 have given a buy rating for AXSM.

Consensus Price Target

$123.25
45.26% Upside
High Forecast$190.00
Average Forecast$123.25
Low Forecast$95.00

According to the 13 analysts' twelve-month price targets for Axsome Therapeutics, the average price target is $123.25. The highest price target for AXSM is $190.00, while the lowest price target for AXSM is $95.00. The average price target represents a forecasted upside of 45.26% from the current price of $84.85.

TypeCurrent Forecast
7/21/23 to 7/20/24
1 Month Ago
6/21/23 to 6/20/24
3 Months Ago
4/22/23 to 4/21/24
1 Year Ago
7/21/22 to 7/21/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
12 Buy rating(s)
12 Buy rating(s)
11 Buy rating(s)
7 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$123.25$122.08$119.67$102.92
Forecasted Upside45.26% Upside59.34% Upside52.79% Upside59.86% Upside
Get Axsome Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.

AXSM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AXSM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Axsome Therapeutics Stock vs. The Competition

TypeAxsome TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.92
2.72
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside45.26% Upside1,425.22% Upside9.99% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/18/2024Bank of America
4 of 5 stars
 Lower TargetNeutral ➝ Neutral$97.00 ➝ $95.00+16.45%
6/12/2024Mizuho
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$106.00 ➝ $106.00+49.15%
6/6/2024HC Wainwright
3 of 5 stars
 Reiterated RatingBuy ➝ Buy$190.00 ➝ $190.00+156.44%
6/5/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$127.00 ➝ $130.00+78.60%
5/7/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$127.00 ➝ $125.00+65.87%
5/7/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$108.00 ➝ $112.00+47.48%
4/29/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeEqual Weight ➝ Overweight$90.00 ➝ $115.00+60.37%
4/10/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$107.00+50.79%
3/26/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$150.00+91.30%
2/21/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$110.00 ➝ $125.00+54.02%
2/6/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$111.00+21.31%
1/16/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$90.00 ➝ $113.00+32.40%
8/7/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
6/22/2023VNET Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingReiterates
12/23/2022BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$62.00 ➝ $98.00+30.44%
11/29/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$65.00 ➝ $85.00+13.73%
11/1/2022Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$95.00+110.41%
10/5/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$125.00+171.27%
9/30/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$92.00 ➝ $90.00+103.85%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 06:10 AM ET.

AXSM Forecast - Frequently Asked Questions

What is Axsome Therapeutics' forecast for 2024?

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Axsome Therapeutics is $123.25, with a high forecast of $190.00 and a low forecast of $95.00.

Should I buy or sell Axsome Therapeutics stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There is currently 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AXSM shares.

Does Axsome Therapeutics's stock price have much upside?

According to analysts, Axsome Therapeutics's stock has a predicted upside of 59.05% based on their 12-month stock forecasts.

Has Axsome Therapeutics been upgraded by Wall Street analysts recently?

Over the previous 90 days, Axsome Therapeutics's stock had 1 upgrade by analysts.

What analysts cover Axsome Therapeutics?

Axsome Therapeutics has been rated by research analysts at Bank of America, Citigroup, HC Wainwright, Mizuho, Morgan Stanley, Robert W. Baird, and Royal Bank of Canada in the past 90 days.

Do Wall Street analysts like Axsome Therapeutics more than its competitors?

Analysts like Axsome Therapeutics more than other "medical" companies. The consensus rating score for Axsome Therapeutics is 2.92 while the average consensus rating score for "medical" companies is 2.72. Learn more on how AXSM compares to other companies.


This page (NASDAQ:AXSM) was last updated on 7/20/2024 by MarketBeat.com Staff

From Our Partners